Kidney Cancer Research News
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur. Urol. (2023)]
September 2, 2023
SETD2 loss and ATR inhibition synergize to promote cGAS signaling and immunotherapy response in renal cell carcinoma
August 1, 2023
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
July 25, 2023
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808
July 3, 2023
Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.
June 28, 2023
A triple dose of optimism: an initial foray into triplet therapy in metastatic renal cell carcinoma
June 23, 2023
Sequencing checkpoint inhibitor therapy in renal cell carcinoma
June 2, 2023
Management of Brain Metastases in Metastatic Renal Cell Carcinoma
June 1, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
March, 2023
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study
March 31, 2023
Adjuvant ipilimumab and nivolumab in renal cell carcinoma: more questions than answers
March 11, 2023
Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States
April 6, 2023
Disease-free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results-Medicare datac
March 1, 2023
Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma
March, 2023
Nivolumab + ipilimumab with immunostimulatory embolization for Stage 4 renal cell carcinoma
February 16, 2023
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3
December 28, 2022
Systemic Therapy Development in Von Hippel-Lindau Disease: An Outsized Contribution from an Orphan Disease
October 28, 2022
Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data
October, 2022
Treatment of Refractory Metastatic Renal Cell Carcinoma
October 13, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
September 1, 2022
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
September 9, 2022
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer
August 23, 2022
Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)
July 1, 2022
Setting a new standard for long-term survival in metastatic kidney cancer
June 1, 2022
Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805
June, 2022
Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma
June, 2022
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma
June 24, 2022
Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma
June 24, 2022
Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma
June, 2022
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
May 27, 2022
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
April 5, 2022
“PROBE”ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer
March 15, 2022
Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
February 1, 2022
Cholesterol Auxotrophy as a Targetable Vulnerability in Clear Cell Renal Cell Carcinoma
December 1, 2021
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease
November 25, 2021
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
November 10, 2021
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study
September 7, 2021
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
August 18, 2021
FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
August 13, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
May 27, 2021
Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research
May 1, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
April 21, 2021
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
March 20, 2021
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
February 20, 2021
The Latest Tweets from Consortium Investigators:
; This thread! Catching up on tweets on a slow Thanksgiving morning. So grateful to have Dr. @KimrynRathmell at the helm of @theNCI.
Today, we're grateful for our incredible community. To the researchers, healthcare professionals, advocates, patients, families, and friends: you are the driving force behind our mission to accelerate cures for kidney cancer.
Wishing you all a joyful Thanksgiving. 🧡
👨⚕️ Dr. @HHammersMD outlines rationale for targeting PTPN2 in RCC—anticipating dual impact on cancer cells and immunomodulation. Excitement builds for upcoming clinical trial results with RCC cohort and KCRC involvement! 🚀🔍 #RCCResearch #KCRC
@HHammersMD driving the immunomodulatory story for #kidneycancer — new trial opening thru @utswcancer DOD kidney cancer clinical trials research consortium! @KidneyCancer @kidneycan @kcCURE
What a win for all of us! 🤩
@KimrynRathmell, renowned #kidneycancer expert and frequent speaker at #KCRS, has been appointed by @POTUS as the new Director of @theNCI.
Congratulations, Dr. Rathmell! 🌟
#KidneyCancerResearch #NCI #CancerMoonshot #AcceleratingCures @OncoAlert
Wonderful news! Congrats @KimrynRathmell @VUMCHemOnc @POTUS
All Uromigos Live 2023 videos are now on our YouTube page:
Enjoy!!
Did you know? We are already gearing up for #KCRS24, and you can pre-register now!
➡️
In the meantime, let's revisit the exciting Trials in Progress session from #KCRS23 with Dr. Naomi Haas of UPenn:
https://youtu.be/UBTwbJFCqSY
While at #UromigosLive, @katy_beckermann shared how she enjoyed the discussion on #belzutifan for patients with #kidneycancer, and explained the need to identify a biomarker for patients who will benefit from this drug. Watch now: https://buff.ly/3u8Q3bd
